than most other biotechs but the share price goes down.
Good cash in the bank Promising new drugs under development- early stages Dacogen revenue stream steady and increasing JNJ,MGI and Eiasi very good partners Good modeling technology-Climb Strong technical organization Management controlling costs- and huge mangement incentive to get share price over $5. Dr. M@@@@@ awarded $5 options Institution accumulation
Other biotechs moving up
There must be something in the works at Supergen. Shareholders are the last to know.
Being Dr. M@@@@@ has not made a deal, has Supergen hired a wall street firm to make a deal?